Cholesterol-Lowering Therapy in Secondary Prevention: Remaining Issues

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 6, 2000, Pages 2092-2098

  Grundy, Scott M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85011454567     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jcem.85.6.6642-2     Document Type: Article

References (54)

1. Endo A. 1992 The discovery and development of HMG CoA reductase inhibitors. J Lipid Res. 33:1569-1582.
2. Smith Jr. SC, Blair SN, Criqui MH, et al. And Secondary Prevention Panel. 1995 Preventing heart attack and death in patients with coronary disease. Circulation. 92:2-4.
3. Rossouw JE, Lewis B, Rifkind BM. 1990 The value of lowering cholesterol after myocardial infarction. N Engl J Med. 323:1112-1119.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 1994 National Cholesterol Education Program: second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol (Adult Treatment Panel II). Circulation. 89:1329-1445.
5. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. 1993 Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 87:1781-1791.
6. The Post Coronary Artery Bypass Graft Trial Investigators. 1997 The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low- dose anticoagulation on obstructive changes in saphenous-vein coronary- artery bypass grafts. N Engl J Med. 336:153-162.
7. Scandinavian Simvastatin Survival Study Group. 1994 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1383-1389.
8. Sacks FM, Pfeffer MA, Moye LA, et al. and for the Cholesterol and Recurrent Events Trial Investigators. 1996 The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1001-1009.
9. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. 1998 Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1349-1357.
10. Navab M, Berliner JA, Watson AD, et al. 1996 The yin and yang of oxidation in the development of the fatty streak. Arterioscler Thromb Vasc Biol. 16:831-842.
11. Ross R. 1995 Cell biology of atherosclerosis. Annu Rev Physiol. 57:791-804.
12. Heinecke JW. 1997 Mechanisms of oxidative damage of low density lipoprotein in human atherosclerosis. Curr Opin Lipidol. 8:268-274.
13. Millican SA, Schultz D, Bagga M, Coussons PJ, Muller K, Hunt JV. 1998 Glucose-modified low density lipoprotein enhances human monocyte che- motaxis. Free Radic Res. 28:533-542.
14. Bhakdi S, Dorweiler B, Kirchmann R, et al. 1995 On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med. 182:1959-1971.
15. Kushwaha RS, McGill Jr. HC. 1998 Diet, plasma lipoproteins and experimental atherosclerosis in baboons (Papio sp.). Hum Reprod Update. 4:420-429.
16. Kita T, Brown MS, Watanabe Y, Goldstein JL. 1981 Deficiency of low density lipoprotein receptors in liver and adrenal gland of the WHHL rabbit, an animal model of familial hypercholesterolemia. Proc Natl Acad Sci USA. 78:2268-2272.
17. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK. 1994 Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest. 93:1885-1893.
18. Law MR, Wald NJ, Thompson SG. 1994 By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J. 308:367-372.
19. Kannel WB, Castelli WP, Gordon T, McNamara PM. 1971 Serum cholesterol, lipoproteins, and the risk of coronary heart disease: The Framingham Study. Ann Intern Med. 74:1-12.
20. Pooling Project Research Group. 1978 Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the Pooling Project Research Group. J Chronic Dis. 31:201-306.
21. Goldbourt V, Holtzman E, Neufeld HN. 1985 Total and high density lipoprotein cholesterol in the serum and risk of mortality: evidence of a threshold effect. Br Med J. 290:1239-1243.
22. Stamler J, Wentworth D, Neaton JD. 1986 Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). J Am Med Assoc. 256:2823-2828.
23. Pedersen TR, Olsson AG, Faergeman O, et al. For the Scandinavian Simvastatin Survival Study Group. 1998 Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 97:1453-1460.
24. Sacks FM, Moye LA, Davis BR, et al. 1998 Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial. Circulation. 97:1446-1452.
25. Grundy SM, Balady GJ, Criqui MH, et al. 1997 When to start cholesterol- lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on risk reduction. Circulation. 95:1683-1685.
26. Grundy SM. 1998 Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 81:18B-25B.
27. Beil U, Grundy SM, Crouse JR, Zech L. 1982 Triglyceride and cholesterol metabolism in primary hypertriglyceridemia. Arteriosclerosis. 2:44-57.
28. de Silva HV, Lauer SJ, Wang J, et al. 1994 Overexpression of human apoli- poprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem. 269:2324-2335.
29. Vega GL, Grundy SM. 1996 Hypoalphalipoproteinemia (low high-density lipoprotein) as a risk factor for coronary heart disease. Curr Opin Lipidol. 7:209-216.
30. McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart JC, Wang CS. 1992 Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res. 33:995-1003.
31. Poapst M, Reardon M, Steiner G. 1985 Relative contribution of triglyceride- rich lipoprotein particle size and number to plasma triglyceride concentration. Arteriosclerosis. 5:381-390.
32. Gofman J, Lindgren F, Elliott H, et al. 1950 The role of lipids and lipoproteins in atherosclerosis. Science. 111:166.
33. Krauss RM. 1998 Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol. 81:13B-17B.
34. Vega GL, Grundy SM. 1991 Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidemia. J Intern Med. 230:341-349.
35. Carlson LA, Rosenhamer G. 1988 Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study to combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 223:405-418.
36. Manninen V, Huttunen JK, Heinonen OP, Tenkanen L, Frick MH. 1989 Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study. Am J Cardiol. 63:42H-47H.
37. Kaplinsky E. The Bezafibrate Infarction Prevention Study. Preliminary results presented at the annual meeting of the European Society of Cardiology, Vienna, Austria, 1998.
38. Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM. 1996 Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation. 94:2146-2153.
39. Lamarche B, Tchernof A, Moorjani S, et al. 1997 Small, dense low density lipoprotein phenotype as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation. 95:69-75.
40. Eisenberg S, Gavish D, Oschry Y, Fairaw M, Deckelbaum RJ. 1984 Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment. J Clin Invest. 74:470-482
41. Vega GL, Grundy SM. 1994 Lipoprotein responses to treatment with lova- statin, gemfibrozil, and nicotinic acid in normolipidemic patients with hy- poalphalipoproteinemia. Arch Intern Med. 154:73-82.
42. East C, Bilheimer DW, Grundy SM. 1988 Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med. 109:25-32.
43. Grundy SM. 1997 Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 95:1-4.
44. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 1997 Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 20:1183-1202.
45. Reaven GM. 1996 Insulin resistance and its consequences: non-insulin- dependent diabetes mellitus and coronary heart disease. In: LeFoith D, Taylor SI, Olefsky JM, eds. Diabetes mellitus. Philadelphia: Lippincott-Raven Publishers; 509-519.
46. DeFronzo RA, Ferrannini E. 1991 Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care. 14:173-194.
47. Bailey CJ. 1993 Metformin an update. Gen Pharmacol. 24:1299-1309.
48. Spiegelman BM. 1998 PPAR-y: adipogenic regulator and thiazolidinedione receptor. Diabetes. 47:507-514.
49. Stampfer MJ, Colditz GA. 1991 Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 20:47-63.
50. Psaty BM, Heckbert SR, Atkins D, et al. 1994 The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med. 154:1333-1339.
51. Bush TL, Barrett-Connor E, Cowan LD, et al. 1987 Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the lipid research clinics program follow-up study. Circulation. 75:1102-1109.
52. Sullivan JM, Vander Zwaag R, Hughes JP. 1990 Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Arch Intern Med. 150:2557-2562.
53. Hulley S, Grady D, Bush T, et al. 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. J Am Med Assoc. 280:605-613.
54. Grundy SM. 1998 The role of cholesterol management in coronary disease risk reduction in elderly patients. Endocrinol Metab Clin North Am. 27:655-675.